For more substantial or chronic conditions (e.g., tendon injuries or longstanding inflammation), treatments may last 46 weeks to see full or peak effects, and some individuals may require longer cycles for maximal benefit
The Foundation of Epitalon Originating from decades of research by Khavinson V.Kh
Although the lipidation of GLP-1 peptides can enhance their binding to albumin, significantly increasing their half-life (this is currently a widely adopted pharmacokinetic enhancement strategy for GLP-1 peptides), lipidation modification is not universally applicable
The KLOW 80mg vial contains KPV 10mg (Lys-Pro-Val, the C-terminal tripeptide of alpha-melanocyte-stimulating hormone at residues 11 to 13, 342.4 g/mol, CAS 64790-08-5), BPC-157 10mg (pentadecapeptide GEPPPGKPADDAGLV, 1419.53 g/mol, CAS 137525-51-0), TB-500 10mg (synthetic thymosin beta 4, 43 residues, 4963.4 g/mol, CAS 77591-33-4) and GHK-Cu 50mg (glycyl-L-histidyl-L-lysine copper(II) complex, 403.9 g/mol, CAS 89030-95-5), co-lyophilised in one container
Cells were counted, pelleted and resuspended in assay buffer (Hanks balanced salt solution buffer (ThermoFisher Scientific), 20 mM HEPES pH 7.4, 1 mM CaCl 2 , 1 mM MgCl 2 , 0,1% Pluronic F-68) to a cell density of 0.5 million cells/mL
